BMS-986368 + famotidine

**BMS-986368 + famotidine** is a combination of two drugs: BMS-986368, an investigational oral small molecule inhibitor of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), and famotidine, a well-established histamine H2 receptor antagonist. BMS-986368 is designed to increase levels of endogenous endocannabinoids by inhibiting their breakdown, thereby potentially promoting muscle relaxation and reducing spasticity, agitation, and seizure activity, notably in conditions like multiple sclerosis, Alzheimer’s disease agitation, and epilepsy. Famotidine is commonly used for managing gastric acid-related disorders but does not share mechanistic overlap with BMS-986368; its inclusion in this combination may be to address gastrointestinal side effects or as supportive care. The combination is not a branded fixed-dose product but describes concurrent therapeutic use[1][6].